Abbott Laboratories (ABT) Stock Forecast & Price Target

$117.95 -0.18 (-0.15%)

(As of 11/26/2024 ET)

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
4

Buy
12

Based on 16 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, and 12 have given a buy rating for ABT.

Consensus Price Target

$130.07
10.27% Upside

According to the 16 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $130.07. The highest price target for ABT is $149.00, while the lowest price target for ABT is $117.00. The average price target represents a forecasted upside of 10.27% from the current price of $117.95.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

ABT Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$130.07	$129.67	$121.80	$117.47
Forecasted Upside	10.27% Upside	13.52% Upside	7.87% Upside	14.38% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	10.63% Upside	24,797.33% Upside	6.96% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$143.00 ➝ $149.00	+26.65%
10/17/2024	Sanford C. Bernstein 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$133.00 ➝ $138.00	+17.37%
10/17/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$143.00 ➝ $146.00	+24.14%
10/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$120.00 ➝ $125.00	+5.91%
10/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$115.00 ➝ $130.00	+10.34%
10/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$107.00 ➝ $117.00	-0.70%
❗[Investor Alert] Under-the-Radar Tech (Ad) While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO Click here for all the details about today's open round of investing.
10/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$131.00 ➝ $133.00	+12.88%
10/14/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Buy	$122.00 ➝ $129.00	+10.28%
10/8/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$125.00 ➝ $130.00	+13.33%
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$120.00 ➝ $124.00	+8.87%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$119.00 ➝ $127.00	+13.95%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$121.00	+20.11%
12/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$116.00 ➝ $121.00	+13.70%
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Peer Perform
4/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$118.00 ➝ $122.00	+9.56%
4/17/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$125.00 ➝ $130.00	+25.05%
3/31/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$90.00 ➝ $102.00	+2.95%
3/30/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $115.00	+16.61%
1/26/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$110.00 ➝ $125.00	+12.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:30 PM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 22, 2024. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories reported a strong quarterly earnings per share (EPS) of $1.21, exceeding the consensus estimate of $1.20, indicating robust financial performance and effective management.
The company achieved a revenue of $10.64 billion for the quarter, surpassing analysts' expectations of $10.55 billion, showcasing its ability to generate sales effectively.
Abbott Laboratories has a solid return on equity of 20.18%, which reflects its efficiency in generating profits from shareholders' equity, making it an attractive investment for those seeking strong returns.
The stock is currently priced at $117.10, which is near its 52-week high of $121.64, suggesting positive market sentiment and potential for further appreciation.
Analysts have a consensus target price of $130.07 for Abbott Laboratories, indicating potential upside from the current stock price, which could attract investors looking for growth opportunities.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

The stock has a relatively high price-to-earnings (P/E) ratio of 35.49, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
Abbott Laboratories has a dividend payout ratio of 66.87%, which indicates that a significant portion of its earnings is being paid out as dividends, leaving less room for reinvestment in growth opportunities.
Despite recent positive performance, the stock has experienced fluctuations, with a 12-month low of $98.95, indicating potential volatility that could concern risk-averse investors.
Insider ownership is relatively low at 0.47%, which may raise concerns about the alignment of management's interests with those of shareholders.
Recent analyst ratings show a mix of hold and buy ratings, with some analysts downgrading their outlook, which could signal uncertainty about the company's future performance.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $130.07, with a high forecast of $149.00 and a low forecast of $117.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 10.27% based on their 12-month stock forecasts.
: Abbott Laboratories has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Mizuho, Morgan Stanley, Oppenheimer, Piper Sandler, Piper Sandler Companies, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, and UBS Group in the past 90 days.
: Analysts like Abbott Laboratories less than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.75 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

This page (NYSE:ABT) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target